October 27, 2013 |
In today's world, brimful as it is with opinion and falsehoods masquerading as facts, you'd think the one place you can depend on for verifiable facts is science. You'd be wrong. Many billions of dollars' worth of wrong. A few years ago, scientists at the Thousand Oaks biotech firm Amgen set out to double-check the results of 53 landmark papers in their fields of cancer research and blood biology. The idea was to make sure that research on which Amgen was spending millions of development dollars still held up. They figured that a few of the studies would fail the test - that the original results couldn't be reproduced because the findings were especially novel or described fresh therapeutic approaches.
September 19, 2013 |
The Amgen Tour of California announced Thursday that its title sponsor, Amgen, the Santa Clarita-based company that conducts cancer-drug research, has re-upped its sponsorship. Kristin Bachochin, executive director of AEG Sports, which owns the race, said the sponsorship was a "multi-year" agreement. Among other race sponsors that have renewed contracts are Champions Systems, an apparel company that renewed for three years. Amgen's sponsorship contract had been up after the 2013 race and had raised questions about the cycling race's future.
June 30, 2013 |
Onyx Pharmaceuticals Inc. on Sunday rejected an unsolicited takeover bid from Amgen Inc., the Thousand Oaks biotech giant. Onyx, headquartered in South San Francisco, confirmed in a statement that it had received a bid of $120 a share from Amgen, but said the offer “significantly undervalued” the company and was “not in the best interest of Onyx or its shareholders. " But Onyx added that it would consider other possible bids. “We are actively exploring the potential to combine Onyx with another company,” Onyx Chief Executive N. Anthony Coles said in the statement.
May 20, 2013 |
SANTA ROSA - Tejay van Garderen rode his bicycle into a hotel meeting room Sunday as if he were corralling a bucking bronco. He reared the cycle up on its back wheel and slammed it down during a well-earned and well-deserved celebration. Van Garderen, a 24-year-old from Bozeman, Mont., took hold of the eighth Amgen Tour of California on Friday by winning the time trial in San Jose; kept his grip Saturday by not faltering on the climb up Mt. Diablo; and by Sunday he might as well have stopped and sampled some of the products at the wineries that dotted the countryside along the 80.7-mile final stage from San Francisco to Santa Rosa.
May 12, 2013 |
ESCONDIDO, Calif. - Lieuwe Westra, red-faced and shaking, was the winner of Sunday's first stage at the Amgen Tour of California, on a day when temperatures on the route were recorded as high as 105 degrees. James Stemper, of the 5-hour Energy/Kenda Racing team, who was awarded the title as most courageous rider for helping lead an early breakaway, said, "Heat was probably the biggest factor of the day. Eventually you could not pedal very hard. " Carter Jones, who rides for the Bissell Pro Cycling team and who earned the most points toward winning the King of the Mountain title as best uphill rider, said, "The heat was brutal.
May 12, 2013 |
SACRAMENTO - Two of the nation's largest biotech companies - Amgen Inc. of Thousand Oaks and Genentech Inc. of South San Francisco - are fighting in Sacramento to keep a tight grip on some of their most lucrative drugs. At stake is a potential market worth tens of billions of dollars for pricey biological medicines they make from human blood, serums, bacterial cultures, viruses and other microorganisms. They are used to treat cancers, immune disorders and many other complex diseases.